Everest Medicines Limited Stock price

Equities

1952

KYG3224E1061

Pharmaceuticals

Market Closed - Hong Kong S.E. 04:08:03 2024-03-28 am EDT 5-day change 1st Jan Change
23.5 HKD +7.31% Intraday chart for Everest Medicines Limited -7.30% +12.44%

Financials

Sales 2023 126M 17.42M 136M Sales 2024 * 691M 95.62M 748M Capitalization 6.49B 898M 7.02B
Net income 2023 -844M -117M -914M Net income 2024 * -724M -100M -784M EV / Sales 2023 48.3 x
Net cash position 2023 * 1.06B 147M 1.15B Net cash position 2024 * 1.05B 145M 1.13B EV / Sales 2024 * 7.87 x
P/E ratio 2023 *
-6.71 x
P/E ratio 2024 *
-8.55 x
Employees 395
Yield 2023 *
-
Yield 2024 *
-
Free-Float 58.91%
More Fundamentals * Assessed data
Dynamic Chart
Transcript : Everest Medicines Limited, 2023 Earnings Call, Mar 27, 2024
Everest Medicines Strengthens Management Team with Appointments of Chief Medical Officer and Chief Product Officer CI
Everest Medicines Terminates Collaboration with Canada’s Providence for mRNA COVID-19 Vaccines MT
Everest Medicines Limited Announces Board Changes CI
Everest Foresees Surge in 2023 Revenue MT
Everest Medicines Limited Provides Earning Guidance for the Year Ended 31 December 2023 CI
Everest Medicines Limited Announces Directorate Changes CI
Everest Medicines Announces New Drug Application Acceptance of Nefecon® in Taiwan for the Treatment of Primary IgA Nephropathy in Adult Patients CI
Everest Medicines Announces Investigational New Drug Application Acceptance of Zetomipzomib in China CI
Everest Medicines Reaffirms Revenue Guidance for the Year 2023 and 2024 CI
Transcript : Everest Medicines Limited - Special Call
Calliditas? Partner Everest Medicines Announces China NMPA?s Approval of Nefecon® for the Treatment of Primary IgA Nephropathy CI
Shortened Post-Thanksgiving Session Keeps Exchange-Traded Funds, Equity Futures Muted Pre-Bell Friday MT
Calliditas Therapeutics Says Partner Secures Regulatory Approval in China for Primary IgA Nephropathy Treatment MT
Calliditas Therapeutics' Partner Secures Approval for Immunoglobulin Nephropathy Treatment in China MT
More news

Latest transcript on Everest Medicines Limited

1 day+7.31%
1 week-6.37%
Current month-2.69%
1 month+8.80%
3 months+13.53%
6 months-3.89%
Current year+12.44%
More quotes
1 week
20.95
Extreme 20.95
25.00
1 month
20.95
Extreme 20.95
30.65
Current year
14.34
Extreme 14.34
30.65
1 year
10.32
Extreme 10.32
32.20
3 years
5.98
Extreme 5.98
82.80
5 years
5.98
Extreme 5.98
104.80
10 years
5.98
Extreme 5.98
104.80
More quotes
Managers TitleAgeSince
Chief Executive Officer 54 22-09-18
President 51 18-11-30
Chief Tech/Sci/R&D Officer 59 23-06-14
Members of the board TitleAgeSince
Director/Board Member 55 20-08-31
Director/Board Member 59 Feb. 08
Chairman 42 17-06-30
More insiders
Date Price Change Volume
24-03-28 23.5 +7.31% 6 616 000
24-03-27 21.9 +1.62% 5,147,000
24-03-26 21.55 -2.93% 8,697,500
24-03-25 22.2 -9.02% 8,656,049
24-03-22 24.4 -2.79% 4,003,164

Delayed Quote Hong Kong S.E., March 28, 2024 at 04:08 am EDT

More quotes
Everest Medicines Ltd is a China-based company principally engaged in the licensing, clinical development and commercialization of therapies to address critical unmet medical needs. The Company is focusing on the research and development of innovative drug candidate. The Company built a portfolio of promising clinical-stage drug candidates across oncology, immunology, cardio-renal disease and infectious disease. The Company mainly provides its products and services in Greater China and other emerging Asia Pacific markets.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
20.23 CNY
Average target price
24.3 CNY
Spread / Average Target
+20.09%
Consensus
  1. Stock
  2. Equities
  3. Stock Everest Medicines Limited - Hong Kong S.E.